3 assets in Borderline Epithelial Tumor Of Ovary

Therapeutic assets addressing Borderline Epithelial Tumor Of Ovary, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Capecitabine Borderline Epithelial Tumor Of Ovary	National Cancer Institute (NCI)	P3	B (60)
Carboplatin Borderline Epithelial Tumor Of Ovary	National Cancer Institute (NCI)	P3	B (60)
Oxaliplatin Borderline Epithelial Tumor Of Ovary	National Cancer Institute (NCI)	P3	B (58)